piracetam has been researched along with Ache in 20 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this open-label study was to assess the effectiveness and tolerability of levetiracetam (LEV) in the treatment of patients with lower lumbar radiculopathy diagnosed by clinical presentation, physical examination, and electrodiagnostics." | 9.14 | Effectiveness of levetiracetam in the treatment of lumbar radiculopathy: an open-label prospective cohort study. ( Anderson, DG; Cifu, DX; Deschner, S; Hamza, MS; Snyder, JW, 2009) |
| "To assess the effectiveness of piracetam for reducing the incidence of painful sickle cell disease crises." | 8.93 | Piracetam for reducing the incidence of painful sickle cell disease crises. ( Al Hajeri, A; Fedorowicz, Z, 2016) |
| "To assess the effectiveness of piracetam for reducing the incidence of painful sickle cell disease crises." | 8.84 | Piracetam for reducing the incidence of painful sickle cell disease crises. ( Al Hajeri, AA; Fedorowicz, Z; Omran, A; Tadmouri, GO, 2007) |
| " Based on the experience with carbamazepine, gabapentin, and lamotrigine, these newer AEDs are being investigated for the management of neuropathic pain." | 8.82 | Oxcarbazepine, topiramate, zonisamide, and levetiracetam: potential use in neuropathic pain. ( Guay, DR, 2003) |
| "Levetiracetam (200-1000 nmol/paw) produced a significant dose-dependent reduction of the paw inflammatory hyperalgesia and edema induced by carrageenan." | 7.78 | The local peripheral antihyperalgesic effect of levetiracetam and its mechanism of action in an inflammatory pain model. ( Micov, AM; Stepanović-Petrović, RM; Tomić, MA; Ugrešić, ND, 2012) |
| "Levetiracetam, a novel antiepileptic drug, has recently been shown to have antinociceptive effects in various animal models of pain." | 7.76 | The antihyperalgesic effect of levetiracetam in an inflammatory model of pain in rats: mechanism of action. ( Micov, A; Popović, B; Stepanović-Petrović, R; Tomić, M, 2010) |
| "Piracetam is a nootropic drug that has reportedly been effective and non-toxic in sickle cell patients, but most studies were not placebo-controlled and included a small number of patients." | 6.71 | Inefficacy of piracetam in the prevention of painful crises in children and adolescents with sickle cell disease. ( Alvim, RC; Brito, AC; Franklin, HM; Oliveira, TF; Paula, MJ; Pires, MA; Rezende, PV; Viana, MB, 2005) |
| "Levetiracetam (LEV) is a novel anticonvulsant with proven antinociceptive properties." | 5.48 | Antinociceptive and pronociceptive effect of levetiracetam in tonic pain model. ( Alfaro-Rodriguez, A; Bandala, C; Bonilla-Jaime, H; Carrillo-Mora, P; Cortes-Altamirano, JL; Olmos-Hernández, A; Reyes-Long, S, 2018) |
| "The purpose of this open-label study was to assess the effectiveness and tolerability of levetiracetam (LEV) in the treatment of patients with lower lumbar radiculopathy diagnosed by clinical presentation, physical examination, and electrodiagnostics." | 5.14 | Effectiveness of levetiracetam in the treatment of lumbar radiculopathy: an open-label prospective cohort study. ( Anderson, DG; Cifu, DX; Deschner, S; Hamza, MS; Snyder, JW, 2009) |
| "To assess the effectiveness of piracetam for reducing the incidence of painful sickle cell disease crises." | 4.93 | Piracetam for reducing the incidence of painful sickle cell disease crises. ( Al Hajeri, A; Fedorowicz, Z, 2016) |
| "To assess the effectiveness of piracetam for reducing the incidence of painful sickle cell disease crises." | 4.84 | Piracetam for reducing the incidence of painful sickle cell disease crises. ( Al Hajeri, AA; Fedorowicz, Z; Omran, A; Tadmouri, GO, 2007) |
| " Based on the experience with carbamazepine, gabapentin, and lamotrigine, these newer AEDs are being investigated for the management of neuropathic pain." | 4.82 | Oxcarbazepine, topiramate, zonisamide, and levetiracetam: potential use in neuropathic pain. ( Guay, DR, 2003) |
| " These results suggest that ceftriaxone, particularly in combinations with ibuprofen, celecoxib, paracetamol, or levetiracetam, may provide useful approach to the clinical treatment of inflammation-related pain." | 3.80 | Antihyperalgesic/antinociceptive effects of ceftriaxone and its synergistic interactions with different analgesics in inflammatory pain in rodents. ( Boškovic, BD; Kovacevic, JM; Micov, AM; Stepanovic-Petrovic, RM; Tomic, MA, 2014) |
| "Levetiracetam (LEV), a new anticonvulsant agent primarily used to treat epilepsy, has been used in pain treatment but the cellular mechanism of this action remains unclear." | 3.78 | Modulation of action potential and calcium signaling by levetiracetam in rat sensory neurons. ( Ayar, A; Ozcan, M, 2012) |
| "Levetiracetam (200-1000 nmol/paw) produced a significant dose-dependent reduction of the paw inflammatory hyperalgesia and edema induced by carrageenan." | 3.78 | The local peripheral antihyperalgesic effect of levetiracetam and its mechanism of action in an inflammatory pain model. ( Micov, AM; Stepanović-Petrović, RM; Tomić, MA; Ugrešić, ND, 2012) |
| "Levetiracetam, a novel antiepileptic drug, has recently been shown to have antinociceptive effects in various animal models of pain." | 3.76 | The antihyperalgesic effect of levetiracetam in an inflammatory model of pain in rats: mechanism of action. ( Micov, A; Popović, B; Stepanović-Petrović, R; Tomić, M, 2010) |
| "Piracetam is a nootropic drug that has reportedly been effective and non-toxic in sickle cell patients, but most studies were not placebo-controlled and included a small number of patients." | 2.71 | Inefficacy of piracetam in the prevention of painful crises in children and adolescents with sickle cell disease. ( Alvim, RC; Brito, AC; Franklin, HM; Oliveira, TF; Paula, MJ; Pires, MA; Rezende, PV; Viana, MB, 2005) |
| "Levetiracetam (LEV) is a novel anticonvulsant with proven antinociceptive properties." | 1.48 | Antinociceptive and pronociceptive effect of levetiracetam in tonic pain model. ( Alfaro-Rodriguez, A; Bandala, C; Bonilla-Jaime, H; Carrillo-Mora, P; Cortes-Altamirano, JL; Olmos-Hernández, A; Reyes-Long, S, 2018) |
| "Piracetam is a prototype of nootropic drugs used to improve cognitive impairment." | 1.39 | Analgesic activity of piracetam: effect on cytokine production and oxidative stress. ( Casagrande, R; Hohmann, MS; Mizokami, SS; Navarro, SA; Serafim, KG; Verri, WA, 2013) |
| "Levetiracetam is an AED with unique mechanisms of action that may have analgesic properties in various pain syndromes." | 1.33 | Levetiracetam as an adjunctive analgesic in neoplastic plexopathies: case series and commentary. ( Dunteman, ED, 2005) |
| "nefiracetam was also blocked by i." | 1.31 | Nonopioid and neuropathy-specific analgesic action of the nootropic drug nefiracetam in mice. ( Rashid, MH; Ueda, H, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (50.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cortes-Altamirano, JL | 1 |
| Reyes-Long, S | 1 |
| Olmos-Hernández, A | 1 |
| Bonilla-Jaime, H | 1 |
| Carrillo-Mora, P | 1 |
| Bandala, C | 1 |
| Alfaro-Rodriguez, A | 1 |
| Navarro, SA | 1 |
| Serafim, KG | 1 |
| Mizokami, SS | 1 |
| Hohmann, MS | 1 |
| Casagrande, R | 1 |
| Verri, WA | 1 |
| Stepanovic-Petrovic, RM | 2 |
| Micov, AM | 2 |
| Tomic, MA | 2 |
| Kovacevic, JM | 1 |
| Boškovic, BD | 1 |
| Rémi, C | 1 |
| Lorenzl, S | 1 |
| Vyhnalek, B | 1 |
| Rastorfer, K | 1 |
| Feddersen, B | 1 |
| Micov, A | 2 |
| Tomić, M | 2 |
| Pecikoza, U | 1 |
| Ugrešić, N | 1 |
| Stepanović-Petrović, R | 2 |
| Al Hajeri, A | 1 |
| Fedorowicz, Z | 2 |
| Viana, MB | 2 |
| Alvim, RC | 2 |
| Hamza, MS | 1 |
| Anderson, DG | 1 |
| Snyder, JW | 1 |
| Deschner, S | 1 |
| Cifu, DX | 1 |
| Popović, B | 1 |
| Ozcan, M | 2 |
| Ayar, A | 2 |
| Ugrešić, ND | 1 |
| Rashid, MH | 1 |
| Ueda, H | 1 |
| Ardid, D | 1 |
| Lamberty, Y | 1 |
| Alloui, A | 1 |
| Coudore-Civiale, MA | 1 |
| Klitgaard, H | 1 |
| Eschalier, A | 1 |
| Ilag, VL | 1 |
| Guay, DR | 1 |
| Dunteman, ED | 1 |
| Pires, MA | 1 |
| Franklin, HM | 1 |
| Paula, MJ | 1 |
| Brito, AC | 1 |
| Oliveira, TF | 1 |
| Rezende, PV | 1 |
| Al Hajeri, AA | 1 |
| Omran, A | 1 |
| Tadmouri, GO | 1 |
| Canpolat, S | 1 |
| Kutlu, S | 1 |
| Myslivecek, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Placebo-Controlled Crossover Trial of Levetiracetam on Ethanol Intake[NCT01168687] | 46 participants (Actual) | Interventional | 2008-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome of this study is to determine the effect of levetiracetam on alcohol consumption as measured by change in # of drinks during each treatment period. (NCT01168687)
Timeframe: During each 14 day treatment period
| Intervention | number of drinks per treatment period (Mean) |
|---|---|
| All Subjects (n = 46) Placebo | 41.2 |
| All Subjects (n = 46) Levetiracetam | 45.4 |
3 reviews available for piracetam and Ache
| Article | Year |
|---|---|
Piracetam for reducing the incidence of painful sickle cell disease crises.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Humans; Pain; Piracet | 2016 |
Oxcarbazepine, topiramate, zonisamide, and levetiracetam: potential use in neuropathic pain.
Topics: Aged; Analgesics, Non-Narcotic; Animals; Carbamazepine; Clinical Trials as Topic; Dose-Response Rela | 2003 |
Piracetam for reducing the incidence of painful sickle cell disease crises.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Humans; Pain; Piracet | 2007 |
3 trials available for piracetam and Ache
| Article | Year |
|---|---|
Painful crises in children with sickle cell disease are not prevented by piracetam.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Child, Preschool; Double-Blind Method; Female; Humans | 2009 |
Effectiveness of levetiracetam in the treatment of lumbar radiculopathy: an open-label prospective cohort study.
Topics: Adult; Aged; Analgesics; Female; Humans; Levetiracetam; Lumbar Vertebrae; Male; Middle Aged; Pain; P | 2009 |
Inefficacy of piracetam in the prevention of painful crises in children and adolescents with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Child, Preschool; Cross-Over Studies; Double-Blind Me | 2005 |
14 other studies available for piracetam and Ache
| Article | Year |
|---|---|
Antinociceptive and pronociceptive effect of levetiracetam in tonic pain model.
Topics: Analgesics; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Leve | 2018 |
Analgesic activity of piracetam: effect on cytokine production and oxidative stress.
Topics: Analgesics; Animals; Cytokines; Male; Mice; Oxidative Stress; Pain; Piracetam | 2013 |
Antihyperalgesic/antinociceptive effects of ceftriaxone and its synergistic interactions with different analgesics in inflammatory pain in rodents.
Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Animals; Anti-Bacterial Agents; Ceftriaxone; Ce | 2014 |
Continuous subcutaneous use of levetiracetam: a retrospective review of tolerability and clinical effects.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female; Humans | 2014 |
Levetiracetam synergises with common analgesics in producing antinociception in a mouse model of painful diabetic neuropathy.
Topics: Acetaminophen; Analgesics; Animals; Aspirin; Diabetic Neuropathies; Dose-Response Relationship, Drug | 2015 |
The antihyperalgesic effect of levetiracetam in an inflammatory model of pain in rats: mechanism of action.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Disease Models, Animal; Hyperalgesia; | 2010 |
Modulation of action potential and calcium signaling by levetiracetam in rat sensory neurons.
Topics: Action Potentials; Analgesics; Animals; Anticonvulsants; Calcium; Dose-Response Relationship, Drug; | 2012 |
The local peripheral antihyperalgesic effect of levetiracetam and its mechanism of action in an inflammatory pain model.
Topics: Adenosine A1 Receptor Antagonists; Adrenergic alpha-Antagonists; Anesthetics, Local; Animals; Carrag | 2012 |
Nonopioid and neuropathy-specific analgesic action of the nootropic drug nefiracetam in mice.
Topics: Analgesia; Animals; Diabetes Mellitus, Experimental; Hyperalgesia; Male; Mice; Mice, Inbred Strains; | 2002 |
Antihyperalgesic effect of levetiracetam in neuropathic pain models in rats.
Topics: Acute Disease; Analgesics; Animals; Carbamazepine; Chronic Disease; Constriction, Pathologic; Diabet | 2003 |
Future Pain Drugs - Europe 2003. 15-16 September 2003, London, UK.
Topics: Acetaminophen; Acetates; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, A | 2003 |
Levetiracetam as an adjunctive analgesic in neoplastic plexopathies: case series and commentary.
Topics: Adult; Aged; Analgesics, Opioid; Anticonvulsants; Brachial Plexus Neuropathies; Dose-Response Relati | 2005 |
Antinociceptive efficacy of levetiracetam in a mice model for painful diabetic neuropathy.
Topics: Analgesics; Animals; Anticonvulsants; Behavior, Animal; Diabetic Neuropathies; Disease Models, Anima | 2008 |
Proceedings: The effects of piracetam on cortical evoked responses in rats stimulated at different postnatal periods.
Topics: Animals; Auditory Perception; Cerebral Cortex; Evoked Potentials; Pain; Piracetam; Pyrrolidinones; R | 1975 |